- Oct 25, 2020
- Reaction score
- East Texas
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated.
Some are saying it is a variant of Ivomec and Hydroxychloroquine